Association of serum levels of TGFBI and COL10A1 with recurrence after endoscopic submucosal dissection in patients with early gastric cancer
10.3760/cma.j.cn341190-20240523-00618
- VernacularTitle:早期胃癌患者血清TGFBI、COL10A1水平与其ESD术后复发的关系研究
- Author:
Ling XUE
1
;
Zhiwei WANG
Author Information
1. 汉中市中心医院肿瘤内科，汉中 723000
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Gastric mucosa;
Endoscopy, gastrointestinal;
Transforming growth factor beta;
Recurrence;
Regression analysis;
ROC curve
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(3):347-352
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the association between serum levels of transforming growth factor beta-induced protein (TGFBI) and type X alpha1 collagen (COL10A1) in patients with early gastric cancer and the recurrence of cancer after endoscopic submucosal dissection (ESD).Methods:A prospective study was conducted involving 110 patients with early gastric cancer who underwent ESD at the Hanzhong Central Hospital from March 2020 to March 2023. This study used a cross-sectional study design, with patients followed up for 1 year post-ESD to assess recurrence. Patients were categorized into the recurrence group and the non-recurrence group. Upon admission, all patients underwent serum testing for TGFBI and COL10A1, and baseline data were collected. The dose-response relationship between serum levels of TGFBI and COL10A1 and the recurrence of cancer after ESD was analyzed.Results:After 1 year of follow-up, recurrence was observed in 17 out of 110 patients with early gastric cancer who underwent ESD, resulting in a recurrence rate of 15.45%. In the recurrent group, the longest diameter of the tumors [(2.37 ± 0.41) cm] was significantly longer than that in the non-recurrent group [(1.85 ± 0.34) cm]. Additionally, serum levels of TGFBI and COL10A1 in the recurrence group were (27.85 ± 6.27) μg/L and (7.03 ± 1.05) μg/L, respectively, which were significantly higher than those in the non-recurrence group [(19.28 ± 4.15) μg/L, (6.14 ± 0.77) μg/L]. The proportion of patients with clinical stages Ⅱa-b and submucosal infiltration depth was significantly greater in the recurrence group [52.94% (9/17), 70.59% (12/17)] than in the non-recurrence group [24.73% (23/93), 43.01% (40/93) in the non-recurrent group. All observed differences were statistically significant ( t = 5.61, 7.17, 4.12, χ2 = 4.26, 4.38, all P < 0.05). The results of the binary logistic regression analysis showed that the longest tumor diameter, high serum levels of TGFBI and COL10A1 expression were risk factors for recurrence after ESD in patients with early gastric cancer ( OR = 65.341, 1.401, 2.855, all P < 0.05). The results of the receiver operating characteristic curve analysis indicated that the areas under the curve for the predictive value of serum TGFBI and COL10A1, both individually and in combination, for recurrence after ESD were 0.869, 0.800, and 0.954, respectively. A linear dose-response relationship was identified between serum levels of TGFBI and COL10A1 and the risk of cancer recurrence after ESD in patients with early gastric cancer (all P < 0.05). Specifically, when serum TGFBI levels exceeded 22.29 μg/L and COL10A1 levels surpassed 6.95 μg/L, the risk of cancer recurrence increased with higher serum levels of both TGFBI and COL10A1. Conclusions:In patients with early gastric cancer, serum levels of TGFBI and COL10A1 are closely related to cancer recurrence after ESD. The higher the serum levels of TGFBI and COL10A1, the greater the risk of recurrence.
